You cannot buy stem cells directly as a consumer in the United States. Stem cell products are regulated by the FDA, and nearly all require federal approval before they can be used in people. The only stem cell products currently approved for sale consist of blood-forming stem cells derived from umbilical cord blood, and those are used exclusively in hospital settings for patients with blood disorders. There is no legitimate retail channel, online store, or clinic where you can simply purchase stem cells off the shelf.
That said, stem cells do change hands in several legitimate ways, from medical treatments to research procurement to private cord blood banking. Understanding how each pathway works will help you sort real options from misleading marketing.
What the FDA Actually Approves
The FDA maintains a list of approved cellular and gene therapy products. The stem cell products on that list are cord blood preparations used to treat disorders of the blood-forming system, things like certain leukemias, immune deficiencies, and inherited blood diseases. Brand names include Hemacord, Allocord, Clevecord, Ducord, and several hospital-affiliated cord blood products. These are administered through transplant centers under physician supervision, not sold to individuals.
A broader category of approved cellular therapies exists, including treatments that use modified immune cells to fight specific cancers. But these are manufactured individually for each patient using that patient’s own cells, processed at specialized facilities, and delivered back to a treatment center. You don’t buy them the way you buy medication at a pharmacy.
What Clinics Are Actually Selling
Hundreds of clinics across the U.S. advertise “stem cell therapy” for conditions like knee pain, back pain, neuropathy, shoulder injuries, and even neurological diseases. These clinics typically charge between $5,000 and $10,000 per injection, with some treatments running above $20,000. The average hovers around $10,000. Knee injections tend to fall in the $5,000 to $10,000 range, while back and shoulder treatments can reach $15,000.
Here is the critical detail: the FDA has not approved any regenerative medicine therapy for orthopedic conditions like osteoarthritis, tendonitis, disc disease, or general joint pain. It has also not approved stem cell therapies for neurological diseases (multiple sclerosis, ALS, Parkinson’s, Alzheimer’s), cardiovascular or lung diseases, macular degeneration, chronic pain, fatigue, or autism. Clinics offering these treatments are operating outside FDA approval.
Many of these clinics use one of two approaches. Some harvest cells from your own body, typically through bone marrow aspiration from the hip or from fat tissue, then reinject them into the problem area. Others use products derived from donated birth tissue like amniotic fluid or umbilical cord material. In either case, the products often contain very few actual stem cells, and some contain none at all. Platelet-rich plasma (PRP), which is simply a concentrated portion of your own blood, is sometimes marketed alongside or even as stem cell therapy. PRP contains growth factors that support tissue repair but does not contain stem cells and has considerably less regenerative potential.
Red Flags at Stem Cell Clinics
The FDA has identified specific warning signs that a clinic is marketing stem cell products illegally. If you’re being charged for a stem cell product outside of a clinical trial, the FDA says you are likely being deceived. Some clinics point to listings on clinicaltrials.gov or claim their product is “registered with the FDA” to imply legitimacy. Neither of those things means a product is legally marketed or has been evaluated for safety.
Documented complications from unregulated stem cell procedures include blindness, tumor formation, serious bacterial infections (including blood infections), neurological damage, and immune reactions. In one well-known case, a boy injected with fetal neural stem cells in Russia later developed tumors in the brain and spine. The risks are not theoretical.
Be skeptical of any clinic that relies on patient testimonials as evidence, claims there are no risks, treats a wide range of unrelated conditions with the same product, or cannot clearly explain the source and composition of what they’re injecting.
Buying Stem Cells for Research
If your search is motivated by scientific research rather than personal treatment, stem cells are available for purchase through biotech suppliers, but only by qualified institutions and investigators. Companies like Lonza manufacture stem cell lines under strict quality controls. Research-grade cells from the NIH cost $500 per vial for nonprofit researchers and $1,500 per vial for commercial buyers. Clinical-grade cells manufactured under pharmaceutical-quality conditions cost $1,000 and $5,000 per vial, respectively.
Obtaining clinical-grade stem cells for use in human trials requires an Investigational New Drug application approved by the FDA, along with proof of a pre-approval meeting with the agency. Researchers must also sign material transfer agreements and comply with intellectual property licenses. This is not a consumer purchase. It is a regulated scientific procurement process with extensive documentation requirements.
Private Cord Blood Banking
The one way an individual can proactively “buy” stem cells is through private cord blood banking at the time of a baby’s birth. This involves collecting blood from the umbilical cord immediately after delivery and storing it in a private facility for potential future use by the child or family members.
Initial collection and processing starts around $845 for standard cord blood banking, with premium processing options running around $1,195. Adding cord tissue storage brings the total to roughly $1,600 to $1,950 upfront. After the first year, annual storage fees run $199 for cord blood alone or $398 for cord blood plus cord tissue. These fees continue every year for as long as you want the cells preserved.
The stored cells are blood-forming stem cells, the same type used in approved transplant therapies. They could be valuable if the child or a family member later develops a blood cancer, immune disorder, or genetic blood disease that requires a transplant. For most families, the cells will never be used. Public cord blood donation, which is free, contributes to a registry that can match donors with unrelated patients in need.
Traveling Abroad for Treatment
Some people travel to countries with less restrictive regulations to receive stem cell treatments unavailable in the U.S. Destinations include clinics in Mexico, Panama, China, India, Thailand, and parts of Eastern Europe. This practice, sometimes called stem cell tourism, carries substantial risks.
Facility quality varies enormously. Protocols are poorly documented and often not shared with patients. In many cases, it is unclear exactly what is being injected. Follow-up care after treatment is rare, which means complications may go undetected until they become serious. The International Society for Stem Cell Research advises patients to verify the source of the stem cells, confirm that the treatment type matches the disease being treated, and watch for clinics that rely on testimonials or claim zero risk.
Patients seeking these treatments are not at fault for wanting options, particularly when facing serious or terminal diagnoses. The problem lies with regulatory gaps that allow unproven treatments to be sold without evidence of safety or effectiveness.
How Legitimate Stem Cell Treatments Reach Patients
In approved medical settings, stem cells reach patients through three main channels. Bone marrow stem cells are harvested through multiple punctures of the hip bone. Mobilized stem cells are collected from peripheral blood after the donor receives medication that pushes stem cells out of the marrow and into the bloodstream. Cord blood stem cells come from umbilical cords collected at birth and stored in public or private banks.
The key regulatory distinction is between “minimal manipulation” and “more than minimal manipulation.” If donor tissue is processed without significant alteration and transplanted to perform its original function (for example, bone marrow cells used to rebuild the blood system), it can proceed under tissue banking rules without a full drug approval. Once cells are engineered, expanded in culture, or used for a purpose different from their natural function, the FDA treats the product as a drug requiring clinical trials and formal approval. Most of what clinics sell as stem cell therapy falls into the second category but skips the approval process.